NASDAQ:VALN

Valneva Stock Forecast, Price & News

$27.77
-0.40 (-1.42 %)
(As of 08/4/2021 12:00 PM ET)
Add
Compare
Today's Range
$27.77
$27.77
50-Day Range
$24.41
$29.03
52-Week Range
$24.16
$31.33
Volume1 shs
Average Volume4,940 shs
Market Capitalization$1.39 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VALN News and Ratings via Email

Sign-up to receive the latest news and ratings for Valneva and its competitors with MarketBeat's FREE daily newsletter.


About Valneva

Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.08 out of 5 stars

Medical Sector

690th out of 1,309 stocks

Biological Products, Except Diagnostic Industry

100th out of 179 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Valneva (NASDAQ:VALN) Frequently Asked Questions

Is Valneva a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Valneva in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Valneva stock.
View analyst ratings for Valneva
or view top-rated stocks.

What stocks does MarketBeat like better than Valneva?

Wall Street analysts have given Valneva a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Valneva wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Valneva's earnings last quarter?

Valneva SE (NASDAQ:VALN) posted its quarterly earnings data on Thursday, May, 20th. The company reported ($0.72) earnings per share for the quarter. The firm had revenue of $27.98 million for the quarter.
View Valneva's earnings history
.

What guidance has Valneva issued on next quarter's earnings?

Valneva updated its FY 2021 earnings guidance on Tuesday, June, 15th. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $96.47 million-126.62 million.

What price target have analysts set for VALN?

4 Wall Street analysts have issued 1-year price targets for Valneva's shares. Their forecasts range from $34.00 to $36.00. On average, they expect Valneva's stock price to reach $35.00 in the next twelve months. This suggests a possible upside of 24.2% from the stock's current price.
View analysts' price targets for Valneva
or view top-rated stocks among Wall Street analysts.

Who are Valneva's key executives?

Valneva's management team includes the following people:
  • Mr. Thomas Lingelbach, Chairman of the Management Board, Pres & CEO (Age 58, Pay $774.08k)
  • Mr. Franck Grimaud, Pres, Chief Bus. Officer & Member of Management Board (Age 54, Pay $487.08k)
  • Mr. David Lawrence, Acting Chief Financial Officer (Age 58, Pay $1.37M)
  • Mr. Frederic Jacotot, VP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board (Age 56, Pay $370.32k)
  • Dr. Juan-Carlos Jaramillo M.D., Chief Medical Officer & Member of the Management Board (Age 50, Pay $391.68k)
  • Mr. Perry Celentano, Interim Chief Operating Officer
  • Laetitia Bachelot-Fontaine, Global Head of Investor Relations & Corp. Communications
  • Mr. Gerald Strohmaier, VP of Human Resource
  • Mr. Christian Taucher, Head of Global Medical Affairs
  • Ms. Susanne Eder-Lingelbach, Head of Clinical Operations

Who are some of Valneva's key competitors?

When did Valneva IPO?

(VALN) raised $99 million in an IPO on Thursday, May 6th 2021. The company issued 3,500,000 shares at a price of $28.24 per share. Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. acted as the underwriters for the IPO.

What is Valneva's stock symbol?

Valneva trades on the NASDAQ under the ticker symbol "VALN."

When did Valneva's quiet period expire?

Valneva's quiet period expired on Tuesday, June 15th. Valneva had issued 2,318,881 shares in its initial public offering on May 6th. The total size of the offering was $61,241,647 based on an initial share price of $26.41. During Valneva's quiet period, insiders and underwriters involved in the IPO were prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Valneva?

Shares of VALN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Valneva's stock price today?

One share of VALN stock can currently be purchased for approximately $28.17.

How much money does Valneva make?

Valneva has a market capitalization of $1.41 billion and generates $126.02 million in revenue each year.

How many employees does Valneva have?

Valneva employs 500 workers across the globe.

What is Valneva's official website?

The official website for Valneva is valneva.com.

How can I contact Valneva?

The company can be reached via phone at 33 2 28 07 37 10 or via email at [email protected]


This page was last updated on 8/4/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.